CIBC Private Wealth Group LLC trimmed its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 24.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 978,632 shares of the biopharmaceutical company's stock after selling 319,361 shares during the period. CIBC Private Wealth Group LLC's holdings in Pfizer were worth $26,286,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Retirement Wealth Solutions LLC bought a new stake in Pfizer during the 4th quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the fourth quarter worth $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer in the fourth quarter worth $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer during the 4th quarter valued at $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.
Pfizer Price Performance
PFE stock traded up $0.19 during trading on Wednesday, hitting $24.73. 41,783,008 shares of the stock traded hands, compared to its average volume of 39,216,512. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $140.26 billion, a price-to-earnings ratio of 17.54, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a one year low of $24.33 and a one year high of $31.54. The company has a 50 day simple moving average of $26.00 and a 200 day simple moving average of $26.84.
Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the previous year, the business earned $0.10 EPS. Pfizer's revenue was up 24.7% compared to the same quarter last year. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Wall Street Analyst Weigh In
PFE has been the topic of several research analyst reports. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group decreased their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Finally, Bank of America restated a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and a consensus price target of $31.92.
Check Out Our Latest Stock Report on Pfizer
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
